Proactive Investors - Run By Investors For Investors

Bristol Myers Squibb showcases positive results of new Phase 3 study evaluating cancer drug Opdivo

The study's results suggest Opdivo extends progression free survival in certain lung cancer patients when taken in combination with chemo and a drug called Yervoy
Cancer cells
The new results will be presented at the American Society of Clinical Oncology's annual meeting

The pharmaceutical giant Bristol Myers Squibb (NYSE:BMY) today revealed positive results from a new study evaluating its lead cancer drug Opdivo.

The pharma company’s Phase 3 CheckMate-227 trial evaluated the effectiveness of Opdivo (nivolumab) plus a low dose of Yervoy (ipilimumab) as well as chemotherapy against chemotherapy alone in patients with advanced non-small cell lung cancer with PD-L1 expression of less than 1% across squamous and non-squamous tumors.

The results suggest that Opdivo in combination with chemotherapy extended progression-free survival versus chemotherapy alone in this subset of patients.

“Results show Opdivo plus chemotherapy improved progression-free survival versus chemotherapy in first-line lung cancer patients whose tumors do not express PD-L1,” said Hossein Borghaei, the study’s investigator and chief of thoracic medical oncology at Fox Chase Cancer center in Philadelphia.

The results from Part 1b of CheckMate 227 will be presented today at the American Society of Clinical Oncology's annual meeting in Chicago.

READ: Bristol-Myers beats 1Q estimates, guides higher for full-year 2018 on drug approvals

CheckMate 227 is an open-label Phase 3 trial aimed at evaluating Opdivo versus platinum-doublet chemotherapy in patients with advanced non small cell lung cancer.

In pre-market trade, Bristol Myers Squibb shares were down about 1% at US$52.60.

View full BMY profile View Profile

Bristol-Myers Squibb Co Timeline

Related Articles

Scientist
December 03 2018
Since September, the group's portfolio has steamed ahead with a number of new and successful clinical trials, as well as a boost from the float of one of its companies on the Nasdaq
An illustration of Ozop's BLIF technique
March 30 2019
A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology
microscope
April 30 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use